Related Experiment Video
Updated: May 31, 2026

Imaging Glioma Initiation In Vivo Through a Polished and Reinforced Thin-skull Cranial Window
Published on: November 20, 2012
RETRACTED: Vulnerability of glioblastoma cells to catastrophic vacuolization and death induced by a small molecule
Satish Srinivas Kitambi1, Enrique M Toledo1, Dmitry Usoskin1
1Division of Molecular Neurobiology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, 17177 Stockholm, Sweden.
Abstract:
Glioblastoma multiforme (GBM) is the most aggressive form of brain cancer with marginal life expectancy. Based on the assumption that GBM cells gain functions not necessarily involved in the cancerous process, patient-derived glioblastoma cells (GCs) were screened to identify cellular processes amenable for development of targeted treatments. The quinine-derivative NSC13316 reliably and selectively compromised viability. Synthetic chemical expansion reveals delicate structure-activity relationship and analogs with increased potency, termed Vacquinols. Vacquinols stimulate death by membrane ruffling, cell rounding, massive macropinocytic vacuole accumulation, ATP depletion, and cytoplasmic membrane rupture of GCs. The MAP kinase MKK4, identified by a shRNA screen, represents a critical signaling node. Vacquinol-1 displays excellent in vivo pharmacokinetics and brain exposure, attenuates disease progression, and prolongs survival in a GBM animal model. These results identify a vulnerability to massive vacuolization that can be targeted by small molecules and point to the possible exploitation of this process in the design of anticancer therapies.
Insights
Researchers discovered that targeting glioblastoma cells with novel compounds called Vacquinols induces massive vacuolization, leading to cancer cell death. This finding offers a new therapeutic strategy for aggressive brain cancer.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Glioblastoma multiforme (GBM) is an aggressive brain cancer with poor prognosis.
- GBM cells may possess unique functions exploitable for targeted therapies.
Purpose of the Study:
- To screen patient-derived glioblastoma cells (GCs) for vulnerabilities.
- To identify novel small molecules for targeted GBM treatment.
Main Methods:
- Screening of patient-derived GCs.
- Chemical synthesis and structure-activity relationship analysis of quinine-derivative NSC13316.
- shRNA screening to identify signaling nodes.
- In vivo pharmacokinetic and efficacy studies in a GBM animal model.
Main Results:
- NSC13316 and its analogs, Vacquinols, selectively compromised GC viability.
- Vacquinols induce cell death via membrane ruffling, macropinocytosis, ATP depletion, and cell rupture.
- MAP kinase MKK4 identified as a critical signaling node.
- Vacquinol-1 demonstrated favorable pharmacokinetics, brain exposure, and therapeutic efficacy in a GBM animal model.
Conclusions:
- Massive vacuolization is a targetable vulnerability in glioblastoma.
- Vacquinols represent a promising class of small molecules for glioblastoma therapy.
- Targeting cellular vacuolization offers a novel approach for anticancer drug design.
Related Concept Videos
Replicative Cell Senescence
Cell Motility through Blebbing
Blebbing Through the Matrix
In multicellular...
Phagocytosis of Apoptotic Cells
Normal cells contain receptors that prevent them from being recognized by phagocytes.
Necrosis
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become anucleated and die, but their...
Cellular Injury IlI: Cellular Death
Cellular Injury V: Apoptosis and Autophagy

